RSS-Feed abonnieren
DOI: 10.1055/a-2066-2068
Endometriumkarzinom. Leitlinie der DGGG, DKG und DKH (S3-Level, AWMF-Register-Nummer 032/034-OL, September 2022) – Teil 2 mit Empfehlungen zur Therapie der Präkanzerosen und des frühen Endometriumkarzinoms, zur operativen Therapie, Strahlen- und medikamentösen Therapie, zu Nachsorge, Rezidiven und Metastasen und zur psychoonkologischen, palliativmedizinischen, patientenedukativen, rehabilitativen und physiotherapeutischen Versorgung
Artikel in mehreren Sprachen: English | deutsch![](https://www.thieme-connect.de/media/gebfra/202308/lookinside/thumbnails/10-1055-a-2066-2068_gf_ll-2_de-1.jpg)
Zusammenfassung
Zusammenfassung Die im April 2018 erstmals publizierte S3-Leitlinie Endometriumkarzinom wurde von April 2020 bis Januar 2022 komplett geprüft und aktualisiert. Dies wurde von der Deutschen Krebshilfe im Rahmen des Leitlinienprogramms Onkologie gefördert und von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), der Arbeitsgemeinschaft Onkologische Gynäkologie (AGO) der Deutschen Krebsgesellschaft (DKG) und der Deutschen Krebshilfe (DKH) federführend koordiniert. Für das Update der Leitlinie wurde die systematisch recherchierte und bewertete Literatur von 2016 bis 2020 verwendet. Alle Statements, Empfehlungen und Hintergrundtexte wurde geprüft und entweder bestätigt oder modifiziert. Soweit erforderlich, wurden neue Statements und Empfehlungen hinzugenommen.
Ziel Durch eine evidenzbasierte risikoadaptierte Therapie können bei den Frauen mit Endometriumkarzinom mit geringem Risiko eine unnötige Radikalität bei der Operation und nicht sinnvolle adjuvante Strahlen- und/oder Chemotherapie vermieden werden. Für die Frauen mit einem Endometriumkarzinom mit hohem Rezidivrisiko definiert die Leitlinie die optimale operative Radikalität sowie die ggf. erforderliche Chemotherapie und/oder adjuvante Strahlentherapie. Dadurch sollen Überleben und Lebensqualität dieser Patientinnen verbessert werden. Die S3-Leitlinie zum Endometriumkarzinom und die auf ihr basierenden Qualitätsindikatoren sollen eine Grundlage für die Arbeit der zertifizierten gynäkologischen Krebszentren sein.
Methoden Die Leitlinie wurde 2018 gemäß den Anforderungen eines S3-Niveaus erarbeitet und 2022 aktualisiert. Dies umfasst zum einen die Adaptation der mittels des DELBI-Instruments gefundenen Quellleitlinien. Zum anderen Evidenzübersichten, die anhand der in systematischen Recherchen nach dem PICO-Schema in ausgewählten Literaturdatenbanken selektierten Literatur erstellt wurden. Mit der systematischen Literaturrecherche und -Bewertung war die Clinical Guidelines Service Group beauftragt. Diese Ergebnisse dienten den interdisziplinären Arbeitsgruppen als Basis für die Erarbeitung von Vorschlägen für Empfehlungen und Statements, die in strukturierten Online-Konsensuskonferenzen und/oder ergänzend im DELPHI-Verfahren modifiziert und konsentiert wurden.
Empfehlungen Der Teil 2 dieser Kurzversion der Leitlinie gibt Empfehlungen zur Therapie der Präkanzerosen und des frühen Endometriumkarzinoms, zur operativen Therapie, Strahlen- und medikamentösen Therapie, zu Nachsorge, Rezidiven und Metastasen des Endometriumkarzinoms und zur psychoonkologischen, palliativmedizinischen, patientenedukativen, rehabilitativen und physiotherapeutischen Versorgungssituation.
Schlüsselwörter
Endometriumkarzinom - Präkanzerosen - operative Therapie - Rezidivtherapie - psychoonkologische Versorgung - onkologische RehabilitationPublikationsverlauf
Eingereicht: 17. März 2023
Angenommen nach Revision: 23. Juni 2023
Artikel online veröffentlicht:
15. August 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References/Literatur
- 1 Travaglino A, Raffone A, Saccone G. et al. Significant risk of occult cancer in complex non-atypical endometrial hyperplasia. Arch Gynecol Obstet 2019; 300: 1147-1154
- 2 Zaino R, Carinelli SG, Ellenson LH. et al. Tumours of the uterine Corpus: epithelial Tumours and Precursors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH. eds. WHO Classification of Tumours of female reproductive Organs. 4th ed. Lyon: WHO Press; 2014: 125-126
- 3 Antonsen SL, Ulrich L, Hogdall C. Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol 2011; 125: 124-128
- 4 Gunderson CC, Fader AN, Carson KA. et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-482
- 5 Luo L, Luo B, Zheng Y. et al. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database Syst Rev 2013; (06) CD009458
- 6 Gallos ID, Yap J, Rajkhowa M. et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207: 266.e1-266.e12
- 7 Baker J, Obermair A, Gebski V. et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012; 125: 263-270
- 8 Koskas M, Uzan J, Luton D. et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 2014; 101: 785-794
- 9 Chan JK, Wu H, Cheung MK. et al. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 2007; 106: 282-288
- 10 Liu T, Tu H, Li Y. et al. Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis. Ann Surg Oncol 2019; 26: 2933-2942
- 11 Frost JA, Webster KE, Bryant A. et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2017; (10) CD007585
- 12 Body N, Grégoire J, Renaud MC. et al. Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer. Gynecol Oncol 2018; 150: 267-273
- 13 Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216: 459-476.e10
- 14 Bogani G, Casarin J, Leone Roberti Maggiore U. et al. Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis. Gynecol Oncol 2020; 158: 77-83
- 15 Kogan L, Matanes E, Wissing M. et al. The added value of sentinel node mapping in endometrial cancer. Gynecol Oncol 2020; 158: 84-91
- 16 Rossi EC, Kowalski LD, Scalici J. et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017; 18: 384-392
- 17 Bogani G, Murgia F, Ditto A. et al. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol 2019; 153: 676-683
- 18 Guo W, Cai J, Li M. et al. Survival benefits of pelvic lymphadenectomy versus pelvic and para-aortic lymphadenectomy in patients with endometrial cancer: A meta-analysis. Medicine (Baltimore) 2018; 97: e9520
- 19 Galaal K, Donkers H, Bryant A. et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2018; (10) CD006655
- 20 Asher R, Obermair A, Janda M. et al. Disease-Free and Survival Outcomes for Total Laparoscopic Hysterectomy Compared With Total Abdominal Hysterectomy in Early-Stage Endometrial Carcinoma: A Meta-analysis. Int J Gynecol Cancer 2018; 28: 529-538
- 21 Galaal K, Bryant A, Fisher AD. et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012; (09) CD006655
- 22 Cusimano MC, Simpson AN, Dossa F. et al. Laparoscopic and robotic hysterectomy in endometrial cancer patients with obesity: a systematic review and meta-analysis of conversions and complications. Am J Obstet Gynecol 2019; 221: 410-428.e19
- 23 Wang L, Liu F. Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer. Arch Gynecol Obstet 2018; 298: 505-510
- 24 Ind T, Laios A, Hacking M. et al. A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: A systematic review and meta-analysis. Int J Med Robot 2017; 13: e1851
- 25 de Lange NM, Ezendam NPM, Kwon JS. et al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. Curr Oncol 2019; 26: e226-e232
- 26 Tanner EJ, Leitao jr. MM, Garg K. et al. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol 2011; 123: 548-552
- 27 Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010; 118: 14-18
- 28 Stelloo E, Nout RA, Osse EM. et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res 2016; 22: 4215-4224
- 29 Klopp A, Smith BD, Alektiar K. et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American society for radiation oncology evidence-based guideline. Practice Guideline. Pract Radiat Oncology 2014; 4: 137-144
- 30 Ortoft G, Hansen ES, Bertelsen K. Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study. Int J Gynecol Cancer 2013; 23: 1429-1437
- 31 AlHilli M, Amarnath S, Elson P. et al. Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma. Int J Gynecol Cancer 2020; 30: 789-796
- 32 Wortman BG, Creutzberg CL, Putter H. et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119: 1067-1074
- 33 Bosse T, Peters EE, Creutzberg CL. et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer–A pooled analysis of PORTEC1 and 2 trials. Eur J Cancer 2015; 51: 1742-1750
- 34 Nout RA, van de Poll-Franse LV, Lybeert ML. et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29: 1692-1700
- 35 Nout RA, Putter H, Jurgenliemk-Schulz IM. et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27: 3547-3556
- 36 Nout RA, Smit VT, Putter H. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823
- 37 León-Castillo A, de Boer SM, Powell ME. et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol 2020; 38: 3388-3397
- 38 de Boer SM, Powell ME, Mileshkin L. et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17: 1114-1126
- 39 de Boer SM, Powell ME, Mileshkin L. et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20: 1273-1285
- 40 de Boer SM, Powell ME, Mileshkin L. et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 295-309
- 41 Nout RA, van de Poll-Franse LV, Lybeert ML. et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29: 1692-1700
- 42 Nout RA, Putter H, Jurgenliemk-Schulz IM. et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27: 3547-3556
- 43 Nout RA, Smit VT, Putter H. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823
- 44 Ørtoft G, Høgdall C, Hansen ES. et al. Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study. J Gynecol Oncol 2020; 31: e22
- 45 Narasimhulu DM, Cope A, Riaz IB. et al. External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2020; 30: 797-805
- 46 Matei D, Filiaci V, Randall ME. et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 2019; 380: 2317-2326
- 47 Reed NS, Mangioni C, Malmstrom H. et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818
- 48 Martin-Hirsch PP, Bryant A, Keep SL. et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011; (06) CD001040
- 49 Johnson N, Bryant A, Miles T. et al. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011; (10) CD003175
- 50 Galaal K, Al Moundhri M, Bryant A. et al. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 2014; (05) CD010681
- 51 de Boer P, Adam JA, Buist MR. et al. Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy. Eur J Radiol 2013; 82: e422-e428
- 52 Nomura H, Aoki D, Michimae H. et al. Effect of Taxane Plus Platinum Regimens vs. Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. JAMA Oncol 2019; 5: 833-840
- 53 Miller DS, Filiaci VL, Mannel RS. et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol 2020; 38: 3841-3850
- 54 Cantrell LA, Havrilesky L, Moore DT. et al. A multi-institutional cohort study of adjuvant therapy in stage I–II uterine carcinosarcoma. Gynecol Oncol 2012; 127: 22-26
- 55 Galaal K, van der Heijden E, Godfrey K. et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2013; (02) CD006812
- 56 Sutton G, Brunetto VL, Kilgore L. et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol 2000; 79: 147-153
- 57 Homesley HD, Filiaci V, Markman M. et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 526-531
- 58 Endometriumcarcinoom. 2011 Zugriff am 25. Juni 2023 unter: https://www.oncoline.nl/endometriumcarcinoom
- 59 Fung-Kee-Fung M, Dodge J, Elit L. et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006; 101: 520-529
- 60 Gadducci A, Cosio S, Fanucchi A. et al. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res 2000; 20: 1977-1984
- 61 Sartori E, Pasinetti B, Carrara L. et al. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 2007; 107: S241-S247
- 62 Smith CJ, Heeren M, Nicklin JL. et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol 2007; 107: 124-129
- 63 Carrara L, Gadducci A, Landoni F. et al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer 2012; 22: 1013-1019
- 64 Creutzberg CL, van Putten WL, Koper PC. et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89: 201-209
- 65 Reddoch JM, Burke TW, Morris M. et al. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 1995; 59: 221-225
- 66 Bristow RE, Purinton SC, Santillan A. et al. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 2006; 103: 709-713
- 67 Salani R, Nagel CI, Drennen E. et al. Recurrence patterns and surveillance for patients with early stage endometrial cancer. Gynecol Oncol 2011; 123: 205-207
- 68 Kadkhodayan S, Shahriari S, Treglia G. et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol 2013; 128: 397-404
- 69 Lalwani N, Dubinsky T, Javitt MC. et al. ACR Appropriateness Criteria(®) pretreatment evaluation and follow-up of endometrial cancer. Ultrasound Q 2014; 30: 21-28
- 70 Ethier JL, Desautels DN, Amir E. et al. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 2017; 147: 158-166
- 71 Jerzak KJ, Duska L, MacKay HJ. Endocrine therapy in endometrial cancer: An old dog with new tricks. Gynecol Oncol 2019; 153: 175-183
- 72 Thigpen JT, Brady MF, Alvarez RD. et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-1744
- 73 Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel) 2020; 12: 2535
- 74 Kokka F, Brockbank E, Oram D. et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010; (12) CD007926
- 75 Covens AL, Filiaci V, Gersell D. et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 120: 185-188
- 76 Vale CL, Tierney J, Bull SJ. et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2012; (8): CD003915.
- 77 Fader AN, Roque DM, Siegel E. et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clin Cancer Res 2020; 26: 3928-3935
- 78 Makker V, Taylor MH, Aghajanian C. et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol 2020; 38: 2981-2992
- 79 Makker V, Colombo N, Casado Herráez A. et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 2022; 386: 437-448
- 80 Le DT, Durham JN, Smith KN. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-413
- 81 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38: 1-10
- 82 Oaknin A, Tinker AV, Gilbert L. et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol 2020; 6: 1766-1772
- 83 Green AK, Feinberg J, Makker V. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. Am Soc Clin Oncol Educ Book 2020; 40: 1-7
- 84 Lee YK, Chung HH, Kim JW. et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117: 922-927
- 85 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, 2020, AWMF-Registernummer: 128/001OL. 2020 Zugriff am 22. Juni 2023 unter: http://leitlinienprogramm-onkologie.de/Palliativmedizin.80.0.html
- 86 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Komplementärmedizin in der Behandlung von onkologischen PatientInnen. Langversion, Registernummer: 032/055OL; 2021. Version 1.1. Zugriff am 22. Juni 2023 unter: https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/
- 87 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Supportive Therapie bei onkologischen Patienten. Langversion 1.1 2017. AWMF-Registernummer 032/054 OL. 2017 Zugriff am 22. Juni 2023 unter: https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie